When was DNAnexus founded?

DNAnexus was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is DNAnexus located?

DNAnexus is headquartered in Mountain View, United States. It is registered at Mountain View, California.

How many employees does DNAnexus have?

As of Feb 28, 2026, the latest employee count at DNAnexus is 286.

Is DNAnexus a funded company?

DNAnexus is a funded company, having raised a total of $473M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 28, 2009.

How much is DNAnexus worth?

The latest valuation of DNAnexus is $***** as of Mar 08, 2022.

When was the latest funding round of DNAnexus?

DNAnexus' latest funding was a $***** Series H round on Mar 08, 2022, with participation from 6 investors.

Where does DNAnexus rank among its competitors?

DNAnexus ranks 2nd amongst 355 active competitors, of which 98 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Evotec, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of DNAnexus?

DNAnexus' top competitors include Evotec, Insitro and Fabric Genomics. Among them, Evotec secured the most recent funding round in January, 2026.

DNAnexus - 2026 Company Profile, Team, Funding & Competitors

Company Details

DNAnexus provides cloud-based genome informatics and data management tools for enterprises and organizations that are engaged in the development and delivery of genomic medicine. The company’s platform enables the companies to analyze raw sequencing data; integrate genomic data with clinical and other phenotypic data, and collaborate seamlessly.

Website: www.dnanexus.com/
Social
Email ID: *****@dnanexus.com
Registered Address: Mountain View, California

Key Metrics

Founded Year

2009

Location

Mountain View, United States

Stage

Series H

Total Funding

$473M in 11 rounds

Latest Funding Round

Series H, Mar 08, 2022, $*****

Post Money Valuation

$***** as on Mar 08, 2022

Investors

Google Ventures & 22 more

Ranked

2^nd among 355 active competitors

Employee Count

286 as on Feb 28, 2026

Similar Companies

Evotec & 457 more

View DNAnexus' full profile

DNAnexus is associated with 7 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BUSINESS DNA s.r.o. CIN: 07846991 , Czech Republic, Active	Jan 29, 2019	-	-
D.N.A Brand s.r.o. CIN: 19178930 , Czech Republic, Active	Mar 23, 2023	-	-
DNA MEDICAL GROUP s.r.o. CIN: 19900376 , Czech Republic, Active	Nov 07, 2023	-	-
DNANEXUS, INC. CIN: 264233063 , United States, Active	Dec 31, 1999	-	147 (As on Dec 31, 2024)	-
DNA MARKETING s.r.o. CIN: 07846975 , Czech Republic, Active	Jan 30, 2019	-	-
DNAX s.r.o. CIN: 03738850 , Czech Republic, Active	Jan 23, 2015	-	-
DNAnexus Czech Republic s.r.o. CIN: 07747365 , Czech Republic, Active	Dec 20, 2018	-	-

DNAnexus has raised a total funding of $473M over 11 rounds. Its first funding round was on Jul 28, 2009. Its latest funding round was a Series H round on Mar 08, 2022 for $*****. 6 investors participated in its latest round. DNAnexus has 23 institutional investors.

Here is the list of recent funding rounds of DNAnexus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 08, 2022	1371914	Series H	8712699	7609868	2921221	5656863
Jun 09, 2020	9902168	Series G	1490855	4231717	3218224	Google Ventures & 4 more
Feb 06, 2019	8603941	Conventional Debt	5114544	1268388	5565395	Innovatus Capital Partners

Access funding benchmarks and valuations. Sign up today!

View details of DNAnexus's funding rounds and investors

The founders of DNAnexus are Arend Sidow, Serafim Batzoglou and Andreas Sundquist. Richard Daly is the CEO of DNAnexus.

Here are the details of DNAnexus' key team members:

Arend Sidow: Co-Founder of DNAnexus and founder of 1 other company.
Contact Info: 1 email address
Serafim Batzoglou: Co-Founder of DNAnexus and founder of 1 other company.
Contact Info: 1 email address
Andreas Sundquist: Former Founder of DNAnexus.
Contact Info: 1 email address
Richard Daly: CEO of DNAnexus. They serve on the board of 1 company.
Contact Info: 1 email address

View details of DNAnexus's Founder profiles and Board Members

DNAnexus' employee count trend

DNAnexus has 286 employees as of Feb 26. Here is DNAnexus's employee count trend over the years:

Uncover DNAnexus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DNAnexus include Evotec, Insitro and Fabric Genomics. Here is the list of Top 10 competitors of DNAnexus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	TVM Capital Life Science, Omega Funds & 20 others	76/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Saints Capital, Claremont Creek Ventures ... & 21 others	70/100
3rd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
4th	Fabric Genomics 2009, Oakland (United States), Acquired	AI-based disease diagnosis and genomic analysis tool for providers	$32.8M	Artis Ventures, UPMC & 12 others	67/100
5th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	New Mountain Capital, Autonomy Ventures & 3 others	66/100
6th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Viola Group, Catalio Capital Management & 14 others	66/100
7th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
8th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$209M	Andreessen Horowitz, CPP Investments & 11 others	64/100
9th	NewLimit 2022, San Francisco (United States), Series B	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$247M	Kleiner Perkins, Lilly & 17 others	64/100
10th	Relation Therapeutics 2020, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100